Information Provided By:
Fly News Breaks for February 13, 2020
Feb 13, 2020 | 09:05 EDT
Lake Street analyst Brooks O'Neil believes Medtronic's MiniMed insulin pump recall "opens the door ever wider" for Tandem Diabetes (TNDM). The analyst believes Tandem would have continued to take share from Medtronic based on the clinically proven performance of its new device. Now, with Medtronic recalling its most advanced device, it seems likely even doctors and patients loyal to Medtronic will be inclined to try Tandem's new system, O'Neil tells investors in a research note. He affirms a Buy rating on the shares with a $100 price target.
News For TNDM;MDT From the Last 2 Days
There are no results for your query TNDM;MDT